Validating Pathway-Level Findings Across Cohorts

What Counts as Pathway-Level Validation?

A pathway-level finding is a claim about a prespecified collection of molecular features, not a claim that every feature in the collection has the same effect. In an independent cohort, validation asks whether a suitably defined pathway-level result recurs under a comparable analysis. The claim might be that a pathway activity score is positively associated with an outcome, or that pathway members are overrepresented among features associated with that outcome. These are different estimands and require different tests.

The pathway must be defined before inspecting the validation results. Record the pathway database and version, identifier, member-feature list, any direction or weights, and how identifiers are mapped to the assay. Also prespecify the outcome, model, direction of the alternative hypothesis, and family of pathway hypotheses to be tested. This makes it possible to distinguish genuine validation from a new analysis chosen after seeing the validation data.

Definition: A pathway-level validation claim is a prespecified hypothesis about a pathway-level estimand that is tested in an independent cohort using a stated pathway definition, outcome, analysis method, and rule for handling unavailable pathway members. Recurrence supports that claim; it does not establish that every pathway member is associated with the outcome or that the pathway causes it.

The earlier material on Validating Molecular Signatures Across Cohorts provides the general replication framework. At pathway level, an additional issue is that both the pathway definition and the subset of its members measurable in each cohort affect what the test means. The cohort-eligibility, measurement-comparability, and multiplicity decisions should therefore be made explicit rather than hidden inside a pathway-analysis software default.

Two Common Pathway-Level Targets

One approach computes a pathway score for each subject from the fixed set of members and tests the score-outcome association. For example, if \(G\) is the prespecified member set and the features have been placed on a defined common scale, an unweighted score could be

S_{ic}=\frac{1}{|G|}\sum_{g\in G} X_{igc},

where \(X_{igc}\) is the standardized measurement of feature \(g\) for subject \(i\) in cohort \(c\). A weighted score instead uses weights frozen from the discovery analysis or a separate training resource. The score definition, including the scaling reference and handling of missing measurements, must be fixed so that the validation cohort is not used to choose a more favorable score.

For a continuous outcome \(Y_{ic}\), one possible validation model is \(Y_{ic}=\alpha_c+\beta_c S_{ic}+\varepsilon_{ic}\). A directional replication hypothesis might be \(H_0:\beta_v\leq 0\) against \(H_a:\beta_v>0\), if a positive association was specified in advance. The coefficient is measured in outcome units per one-unit increase in the pathway score. Ordinary least-squares inference assumes independent subjects, a correctly specified conditional mean, and constant error variance for the usual standard error; exact small-sample \(t\) inference additionally assumes normally distributed errors. If these assumptions are doubtful, use an appropriate robust or resampling procedure specified in advance.

A second approach tests enrichment: are pathway members unusually concentrated among features passing a prespecified feature-level threshold? Over-representation analysis using the hypergeometric distribution is a standard example. It tests a thresholded set and does not directly estimate a pathway activity effect. Its result depends on the threshold and on the universe of features that could have been selected.

Key distinction: A score-based test evaluates an association for a defined aggregate measurement. An over-representation test evaluates whether a selected feature set contains more pathway members than expected under a specified sampling model. The two methods answer different questions; choosing between them after seeing which gives the smaller \(p\)-value invalidates the prespecified testing plan.

Coverage, Definitions, and the Tested Universe

Let the original pathway contain \(M\) features. If only \(m\) are measurable and reliably mapped in the validation cohort, the coverage fraction is \(m/M\). Report both the count and fraction, along with the mapping rules. A pathway test on the available subset concerns that subset, not automatically the original full pathway. If the available members are a nonrandom subset—for example, the assay omits low-abundance or difficult-to-measure features—the result may not represent the full pathway.

For over-representation analysis, define the universe as the features that were eligible for the feature-level analysis in that cohort, after quality control and mapping. Let \(N\) be the number of eligible features, \(K\) the number of those features belonging to the pathway, \(n\) the number selected by the feature-level rule, and \(k\) the observed number of selected pathway members. Under the null model that the \(n\) selected features are a uniformly chosen subset of the \(N\) eligible features, \(X\), the pathway-member count among them, has a hypergeometric distribution:

P(X=x)=\frac{\binom{K}{x}\binom{N-K}{n-x}}{\binom{N}{n}}, \qquad p_{\text{enrich}}=P(X\geq k)= \sum_{x=k}^{\min(K,n)} \frac{\binom{K}{x}\binom{N-K}{n-x}}{\binom{N}{n}}.

This null model requires a well-defined eligible universe and treats each eligible feature as equally likely to enter the selected set under the null. If feature selection probabilities differ substantially, or features are strongly dependent, the simple hypergeometric model may be poorly calibrated. A pathway database may also contain overlapping sets, so a result for one pathway is not independent evidence from results for all other pathways.

Worked Example: Testing a Prespecified Pathway Score

Suppose a discovery analysis prespecified a five-feature pathway score and found a positive association with a continuous outcome. In an independent validation cohort, the same five features are measured, standardized by the frozen procedure, and combined with the same equal weights. A regression of outcome on score and prespecified covariates estimates \(\hat{\beta}_v=0.25\) outcome units per score unit, with \(SE=0.12\) and \(df=96\). Assume independent subjects and a model for which the reported standard error is appropriate. The directional alternative \(H_a:\beta_v>0\) was set before validation.

The test statistic is \(t=\hat{\beta}_v/SE=0.25/0.12=2.083\). With 96 degrees of freedom, the one-sided \(p\)-value is approximately 0.020. At \(\alpha=0.05\), this is evidence for a positive pathway-score association in this cohort. The estimated association is 0.25 outcome units per one-unit increase in the defined score.

For context, a two-sided 95% confidence interval uses \(t_{0.975,96}\approx1.985\): \(0.25\pm1.985(0.12)=0.25\pm0.2382\), giving approximately \([0.0118,0.4882]\) outcome units per score unit. This interval describes uncertainty in the cohort-specific coefficient under the model; it does not imply that every member feature has a positive association. If many pathways were tested, the nominal \(p\)-value alone would not establish significance after multiplicity adjustment.

Worked Example: Enrichment With Partial Pathway Coverage

A prespecified pathway contains six features. In a hypothetical validation assay, four are eligible and mapped, so coverage is \(4/6=0.667\), or 66.7%. The feature-level analysis tested \(N=20\) eligible features; \(n=5\) passed its prespecified threshold. Of the four eligible pathway members, \(k=3\) passed. The correct universe is the 20 eligible features, not all features in the genome or all entries in the pathway database.

Under the hypergeometric null, the upper-tail probability is \(P(X\geq3)=\{\binom{4}{3}\binom{16}{2}+\binom{4}{4}\binom{16}{1}\}/\binom{20}{5}\). The numerator is \(4(120)+1(16)=496\), and \(\binom{20}{5}=15504\). Thus \(p_{\text{enrich}}=496/15504\approx0.0320\).

This is nominal evidence of enrichment among the four measurable members, conditional on the stated null model and threshold. It is not evidence that the complete six-feature pathway was tested: two members were unavailable. Nor does it mean there is a 3.2% probability that the null is true. The limited coverage and possible unequal feature-selection probabilities should be considered when interpreting the result.

Multiplicity and the Meaning of Recurrence

A validation analysis often tests multiple pathways. The family should include the pathways actually considered for validation, including any prespecified directional versions of the hypotheses. If a pathway was selected because it looked strongest in the discovery cohort, testing it in an independent cohort can still provide valid confirmation, provided the validation hypothesis and analysis are fixed independently of the validation outcomes. If validation results are used to choose among alternative pathway definitions, thresholds, or scoring methods, those choices enlarge the testing family.

For a family of \(m\) pathway tests, the Benjamini–Hochberg procedure controls the false discovery rate under its standard independence assumptions and also under certain forms of positive dependence. Order the \(p\)-values \(p_{(1)}\leq\cdots\leq p_{(m)}\). At target level \(q\), find the largest \(i\) for which \(p_{(i)}\leq iq/m\), then reject the hypotheses ranked \(1\) through \(i\). If dependence does not meet the procedure’s conditions, use a method justified for the dependence structure, such as a more conservative family-wise procedure, or an appropriately designed resampling approach.

Worked Example: Adjusting Across Prespecified Pathways

Suppose four pathways were prespecified for validation, and their hypothetical cohort-specific \(p\)-values are 0.008, 0.021, 0.040, and 0.200. Apply Benjamini–Hochberg at \(q=0.05\). The ordered values are already listed in increasing order. The rank-specific cutoffs are \(0.05(1/4)=0.0125\), \(0.05(2/4)=0.0250\), \(0.05(3/4)=0.0375\), and \(0.05(4/4)=0.0500\).

The first two comparisons pass: \(0.008\leq0.0125\) and \(0.021\leq0.0250\). The third does not, because \(0.040>0.0375\), and the fourth does not. The largest passing rank is therefore \(i=2\), so the first two pathway hypotheses are rejected by this procedure. This controls the expected proportion of false rejections among the rejected hypotheses at the target level under the stated dependence conditions; it does not guarantee that each reported pathway has a 5% probability of being false.

Diagnostics, Alternatives, and Limitations

Before interpreting a result, check that the validation analysis actually matches the prespecified one. Confirm feature identifiers and pathway version, coverage and missingness, score construction or eligible universe, outcome coding, effect direction, and the complete set of tested pathways. For score models, examine residual and influence diagnostics and verify that the score has usable variation. For threshold-based enrichment, check whether small changes in the feature threshold alter the selected set; threshold sensitivity is a warning that the conclusion is driven by an arbitrary cutoff. These checks diagnose fragility but should not be used to select whichever analysis yields significance.

The principal alternatives have different strengths. A frozen subject-level pathway score preserves a continuous aggregate and can yield an effect estimate with units, but its interpretation depends on the score scale, weights, and member coverage. Over-representation analysis is simple and interpretable as a set-count comparison, but discards the magnitudes and ordering of feature-level evidence and depends on a threshold. Ranked-set enrichment methods use more of the feature ranking, but their null procedure and treatment of correlated features must be appropriate to the data. Do not present these methods as interchangeable tests of one identical estimand.

Pathways are overlapping, database-dependent representations of biology. A significant aggregate result can be driven by a subset of members, shared members across pathways, or a few high-leverage measurements. Conversely, a nonsignificant result may reflect limited sample size, incomplete coverage, or a changed measurement scale rather than absence of a biological association. In each case, report the pathway definition, coverage, effect estimate where available, uncertainty, testing family, and adjustment method. A pathway-level finding is evidence at the level of the stated analysis—not proof of a mechanism or causal process.

Common Mistakes

Changing the pathway after seeing validation data. Choosing a database version or subset because it gives the strongest result makes the nominal test too optimistic. Freeze the definition or account for the selection in the testing plan.
Using the wrong enrichment universe. Comparing selected assay features with all genes ignores what could actually have been selected. Use the eligible, mapped features from the cohort’s analysis.
Treating partial coverage as complete validation. A result based on a subset concerns the measured members; report coverage and avoid claims about unmeasured members.
Calling one nominal \(p\)-value replication after testing many pathways. Apply the planned multiplicity procedure to the full relevant family and report adjusted results.
Interpreting pathway recurrence as recurrence of every gene. Aggregate significance does not imply member-by-member replication or causation.

Key takeaway: A defensible pathway validation has a frozen biological definition, a clear pathway-level estimand, an analysis suited to that estimand, cohort-specific coverage and universe, and multiplicity control across the hypotheses considered. The conclusion should be no broader than those choices support.

Check Your Understanding

Answer each question, then compare with the solutions below.

A pathway has 12 prespecified members, of which 9 are eligible in a validation cohort. What coverage should be reported, and what does a test on those nine members directly concern?
Why is the full genome generally not the appropriate universe for hypergeometric over-representation if only a subset of features could pass the cohort’s quality-control and association analysis?
Three pathways have ordered \(p\)-values 0.010, 0.030, and 0.040. Using Benjamini–Hochberg with \(m=3\) and \(q=0.05\), which hypotheses are rejected?
What does a positive validation coefficient for a fixed pathway score establish, and what does it not establish about individual member features?

Solutions. (1) Coverage is \(9/12=0.75\), or 75%. The test directly concerns the available nine-member subset under its stated score or enrichment definition, not all 12 members. (2) Features that could not be selected were not part of the relevant sampling universe; including them changes \(N\) and the null distribution. (3) The cutoffs are \(0.05/3=0.0167\), \(2(0.05)/3=0.0333\), and \(0.0500\). All three ordered values pass their respective cutoffs, so all three hypotheses are rejected by this procedure. (4) It supports a positive association for the defined aggregate score in that cohort, subject to the model and multiplicity plan. It does not show that every member feature has a positive effect, nor that the pathway causes the outcome.